On April 2, 2026 the U.S. Food and Drug Administration accepted Ultragenyx Pharmaceutical’s resubmitted Biologics License Application for UX111, an AAV9‑based gene therapy that targets Sanfilippo syndrome type A. The acceptance follows a Complete Response Letter issued in July 2025 and an Incomplete Response Letter in February 2026, both of which prompted the company to submit additional data and address chemistry, manufacturing, and controls concerns.
The resubmission included extensive long‑term clinical data extending up to eight years of follow‑up. The data demonstrate sustained improvements in cognitive, communication, and motor function, as well as a measurable reduction in cerebrospinal fluid heparan sulfate levels, the biomarker that drives the disease’s neurodegeneration.
Regulatory designations accompanying the application include Regenerative Medicine Advanced Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug status in the United States, as well as PRIME and Orphan Drug status in the European Union. The FDA has set a PDUFA action date of September 19, 2026, and the company is seeking accelerated approval, which could shorten the time to market for the first therapy for this fatal, untreatable disease.
The acceptance strengthens Ultragenyx’s pipeline and positions the company as a leading developer of rare‑disease gene therapies. If approved, UX111 would generate a new revenue stream in a market of 3,000–5,000 patients in commercially accessible geographies, and it would reinforce the company’s reputation for delivering innovative treatments for ultra‑rare conditions.
Manufacturing of UX111 will be conducted in the United States at Ultragenyx’s facilities, ensuring compliance with U.S. regulatory standards and supporting the company’s strategy of domestic production for its gene‑therapy portfolio. The next steps involve the FDA’s review of the clinical data and the potential for market entry, which would have a significant impact on the company’s financial performance and long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.